Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell Stabilizes Near Multi-Year Lows as Phase 3 QOL Data Validates Safety Profile Ahead of Top-Line Efficacy Readout

By The Northwire Desk — AI Analysis Apr 20, 2026 · 07:30 BCT · 6.09 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • Most Recent Release (April 20, 2026): BriaCell presented positive Phase 3 Quality of Life (QOL) and Phase 2 Biomarker data at the 2026 AACR Annual Meeting.
  • Phase 3 QOL Findings: In metastatic breast cancer patients heavily pretreated with prior therapies, global health status remained stable through early/mid-treatment. Emotional and cognitive functioning were maintained, and symptom burden was stable. Safety profile is favorable for decentralized treatment approaches (home self-administration).
  • Biomarker Insights: Phase 2 analysis identified mitotic circulating tumor cells (CTCs) as a marker for aggressive disease; patients with these derived survival benefit from targeted therapy. PD-L1 expression in tumor macrophage fusion cells (TMFCs) correlated with improved progression-free survival (PFS), regardless of initial tissue biopsy scores.
  • Historical Context: This follows a sequence of positive safety updates (DSMB recommendations in Feb 2026, Oct/Nov 2025), Phase 2 survival data showing >18-47 month survivors (Jan 2026), and a $30M public offering closing in Jan 2026.
  • Asset Transaction: In March 2026, BriaPro acquired exclusive rights to soluble CD80 (sCD80) from BriaCell for ~C$1.18M in shares, increasing BriaCell's stake in the subsidiary to 78%.
Material Impact
  • Incremental Validation: The QOL data reinforces the safety and tolerability profile already confirmed by five consecutive DSMB positive recommendations. It does not introduce new efficacy endpoints (Overall Survival) which remain the primary driver for valuation.
  • Market Expectations: Given the Phase 3 enrollment is on track for H1 2026 top-line data, QOL presentations are standard regulatory and investor communication steps rather than unexpected catalysts. The market has already priced in the safety profile through previous DSMB announcements.
  • Stock Price Context: The stock has declined ~93% from its April 2025 high ($84.50) to current levels (~$6). While positive, this news is unlikely to trigger a "Game Changer" re-rating without top-line Overall Survival (OS) data.
  • Financing Impact: The $30M offering in January 2026 provided runway but caused significant dilution and price suppression. This news supports the use of proceeds for advancing immunotherapy programs, validating capital allocation.
BCT · Price
Company Overview
  • Company: BriaCell Therapeutics Corp focuses on immunotherapy for cancer, specifically metastatic breast cancer.
  • Flagship Project: Bria-IMT (allogenic whole cell-based cancer vaccine) combined with an immune checkpoint inhibitor (CPI).
  • Trial Status: Pivotal Phase 3 study (Bria-ABC) in metastatic breast cancer is ongoing under FDA Fast Track designation. Enrollment exceeds expectations (>160 patients enrolled as of Dec 2025).
  • Secondary Pipeline: Bria-OTS+ platform (off-the-shelf immunotherapy), sCD80 asset (acquired via subsidiary BriaPro), and collaborations with Receptor.AI for small molecules.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other